Drugs / Pemvidutide
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04972396 | Sep 2021 → May 2022 | metabolic dysfunction-associated steatohepatitis | Altimmune, Inc. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07009860 | Jun 2025 → Mar 2027 expected | alcoholic liver disease | Altimmune, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06987513 | May 2025 → May 2026 overdue | alcohol-related disorders | Altimmune, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05989711 | Jul 2023 → Nov 2025 | metabolic dysfunction-associated steatohepatitis | Altimmune, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pemvidutide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04972396 ↗ |
| Action | Activate | “GLP-1-glucagon dual receptor agonists such as pemvidutide have shown promise in treating metabolic dysfunction-associated steatohepatitis (MASH).” PMID 41237796 ↗ Nov 2025 |
| Route | Subcutaneous | “Injected subcutaneously (SC)” NCT04972396 ↗ |